Physician profile

Dennis Kuo

Anesthesiology · Anaheim, CA

NPI 1295140739

$5,951.02

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$468.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $1,829.74 2019-2024
Abbott Laboratories $1,594.95 2019-2020
Nevro Corp. $1,235.50 2019-2024 Senza
Medtronic, INC. $930.13 2021-2024 Intellis Adaptivestim
Spr Therapeutics, INC $157.13 2019
Pfizer INC. $119.03 2020
Saluda Medical Americas, INC. $31.56 2023 Evoke Scs
Stryker Corporation $24.02 2019
Valinor Pharma, LLC $14.61 2023 Movantik
Ibsa Pharma INC. $14.35 2023 Tirosint, Licart

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dennis Kuo

$5,951.02

in general payments reported 2019-2025

Years
2019-2024
Top company
Boston Scientific Corporation

https://glasscript.com/doctor/912996/dennis-kuo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.